Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...
Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...
Hundreds of malaria patients enrolled in a phase 3 clinical trial in Gabon, West Africa, were successfully treated with a one ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...
The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the ...
Gabonese researchers at the Lambarene Medical Research Center (CERMEL) have achieved a major scientific breakthrough in the fight against endemic malaria by developing a new, highly effective ...
The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Scientists have created the first new anti- malaria drug in a quarter of a century to combat resistance to existing ...
Novartis has developed a new drug, GanLum, which shows over 97% effectiveness in a phase III trial against malaria. The drug aims to counteract rising resistance to current treatments, notably ...
LONDON (Reuters) - Sending daily text message reminders to health workers can mean nearly 25 percent more children are properly treated for malaria, according to the results of a six-month trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback